Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03897881




Registration number
NCT03897881
Ethics application status
Date submitted
29/03/2019
Date registered
1/04/2019
Date last updated
3/06/2024

Titles & IDs
Public title
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Scientific title
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
Secondary ID [1] 0 0
mRNA-4157-P201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - mRNA-4157
Other interventions - Pembrolizumab

Experimental: mRNA-4157 and Pembrolizumab - Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.

Active Comparator: Pembrolizumab - Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.


Treatment: Drugs: mRNA-4157
Individualized Neoantigen Therapy

Other interventions: Pembrolizumab
Intravenous infusion
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging
Timepoint [1] 0 0
Up to 5 years
Secondary outcome [1] 0 0
Distant Metastasis-Free Survival (DMFS), Assessed Using Radiological Imaging
Timepoint [1] 0 0
Up to 5 years
Secondary outcome [2] 0 0
Number of Participants With Adverse Events (AEs)
Timepoint [2] 0 0
Baseline through 100 days after last mRNA-4157 dose (for mRNA-4157 and Pembrolizumab combination arm) and up to 90 days after last pembrolizumab dose (for Pembrolizumab only arm) (up to a total of 5 years for both arms)
Secondary outcome [3] 0 0
Number of Participants Who Discontinued Due to AEs
Timepoint [3] 0 0
Baseline through 100 days after last mRNA-4157 dose (for mRNA-4157 and Pembrolizumab combination arm) and up to 90 days after last pembrolizumab dose (for Pembrolizumab only arm) (up to a total of 5 years for both arms)

Eligibility
Key inclusion criteria
Key

- Resectable cutaneous melanoma metastatic to a lymph node and at high risk of
recurrence

- Complete resection within 13 weeks prior to the first dose of pembrolizumab

- Disease free at study entry (after surgery) with no loco-regional relapse or distant
metastasis and no clinical evidence of brain metastases

- Has an formalin fixed paraffin embedded (FFPE) tumor sample available suitable for
sequencing

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

- Normal organ and marrow function reported at screening

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior malignancy, unless no evidence of that disease for at least 5 years prior to
study entry

- Prior systemic anti-cancer treatment (except surgery and interferon for thick primary
melanomas. Radiotherapy after lymph node dissection is permitted)

- Live vaccine within 30 days prior to the first dose of pembrolizumab

- Transfusion of blood or administration of colony stimulating factors within 2 weeks of
the screening blood sample

- Active autoimmune disease

- Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy
within 7 days prior to the first dose of pembrolizumab

- Solid organ or allogeneic bone marrow transplant

- Pneumonitis or a history of (noninfectious) pneumonitis that required steroids

- Prior interstitial lung disease

- Clinically significant heart failure

- Known history of human immunodeficiency virus (HIV)

- Known active hepatitis B or C

- Active infection requiring treatment

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/07/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
9/09/2029
Actual
Sample size
Target
267
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Melanoma Institute Australia - North Sydney
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Affinity Clinical Research - Murdoch
Recruitment hospital [5] 0 0
St John of God Hospital Subiaco - Subiaco
Recruitment postcode(s) [1] 0 0
2060 - North Sydney
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
6150 - Murdoch
Recruitment postcode(s) [5] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ModernaTX, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157
and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in
participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03897881
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Moderna Clinical Trials Support Center
Address 0 0
Country 0 0
Phone 0 0
1-877-777-7187
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03897881